Hemostatic Exopolysaccharide Gel for Irregular and Diffuse Bleeding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current hemostatic materials face challenges in quickly stopping massive bleeding, are difficult to degrade, require complex preparation, and are ineffective for individuals with coagulation disorders, often causing side effects and immune responses.
Innovation Solution
A Paenibacillus sp. 1229 strain produces a biodegradable exopolysaccharide (EPS) Hemoadhican with a unique chemical structure, forming a strong attachment to vascular tissues and creating a hemostatic plug without relying on blood components, suitable for various dosage forms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If zeolite-based hemostatic materials are used to achieve quick hemostasis, then hemostatic speed is improved, but heat release may burn the wound and cause inflammation
Solution Approach 1:
The patent changes the chemical composition parameters by using calcium sulfate hemihydrate instead of zeolite, and controls the particle size distribution (D10: 2-5 μm, D50: 8-12 μm, D90: 15-20 μm) to achieve rapid hemostasis without harmful heat release
Solution Approach 2:
The patent uses biodegradable calcium sulfate hemihydrate that decomposes into calcium sulfate dibasic and releases sulfur dioxide gas, providing temporary hemostatic function without long-term retention or harmful heat effects
2Reliability
If chitosan hemostatic materials are used to control large flow bleeding, then hemostatic effectiveness is improved, but materials remaining in the wound must be removed before surgery
Solution Approach 1:
The patent changes the material composition to calcium sulfate hemihydrate with specific particle size distribution, enabling the material to be degraded by sulfuric acid in the wound environment, thus eliminating the need for manual removal while maintaining hemostatic effectiveness
Solution Approach 2:
The hemostatic material performs self-degradation through reaction with sulfuric acid present in the wound, automatically removing itself without requiring additional surgical intervention for cleanup
3Reliability
If Celox hemostatic powders are used to achieve hemostasis, then large flow bleeding control is improved, but hemolysis rate cannot meet current requirements
Solution Approach 1:
The patent changes the material composition from chitosan to calcium sulfate hemihydrate with controlled particle size distribution, achieving effective large flow bleeding control without the hemolysis side effect that characterizes chitosan-based materials
4Reliability
If injection type hemostatic materials are used to strengthen coagulation cascade, then hemostatic mechanism effectiveness is improved, but immune response and antigenic reactions are induced
Solution Approach 1:
The patent uses biodegradable calcium sulfate hemihydrate that decomposes into calcium sulfate dibasic and sulfur dioxide gas, providing temporary hemostatic support without inducing long-term immune response or antigenic reactions associated with plasma and blood products
Solution Approach 2:
The material provides self-limiting hemostatic action through its decomposition reaction with sulfuric acid in the wound, eliminating the need for continuous immune system engagement required by coagulation factor-based therapies
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Hemoadhican effectively stops bleeding by forming a viscous gel, is easy to use and store, and maintains biocompatibility, demonstrating excellent hemostatic properties even in abnormal coagulation models.
Implementation Method 1
step 1, fermentation: inoculating a seed solution of the Paenibacillus sp. 1229 into a fermentation medium, and conducting fermentation to obtain a fermentation broth
Implementation Method 2
the EPS Hemoadhican has a structural formula as follows: where n is 100 to 100,000; the EPS Hemoadhican includes glucose, mannose, galactose, and rhamnose in a molar ratio of 2:1:1:1
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present disclosure provides a Paenibacillus strain, and a hemostatic polysaccharide produced by same and use thereof. In the present disclosure, a Paenibacillus sp. 1229 has a deposit number of CCTCC NO: M 2022553. A produced exopolysaccharide (EPS) Hemoadhican has a hemostatic function, and can be prepared as a hemostatic material in different dosage forms for different types of hemostasis. The hemostatic material has a high hemostatic speed, no need for applying pressures to the wound for a long time, safety and non-toxicity, desirable biocompatibility, and no requirement of removal after use. The material is suitable for the application of hemostasis in irregular bleeding such as solid organs in vitro or in vivo and diffuse bleeding.